BR112022019672A2 - Composições de vacina para o tratamento de coronavírus - Google Patents
Composições de vacina para o tratamento de coronavírusInfo
- Publication number
- BR112022019672A2 BR112022019672A2 BR112022019672A BR112022019672A BR112022019672A2 BR 112022019672 A2 BR112022019672 A2 BR 112022019672A2 BR 112022019672 A BR112022019672 A BR 112022019672A BR 112022019672 A BR112022019672 A BR 112022019672A BR 112022019672 A2 BR112022019672 A2 BR 112022019672A2
- Authority
- BR
- Brazil
- Prior art keywords
- coronavirus
- compositions
- treatment
- vaccine compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002237P | 2020-03-30 | 2020-03-30 | |
| US202063070150P | 2020-08-25 | 2020-08-25 | |
| PCT/IB2021/000190 WO2021198769A1 (en) | 2020-03-30 | 2021-03-30 | Vaccine compositions for the treatment of coronavirus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019672A2 true BR112022019672A2 (pt) | 2023-03-07 |
Family
ID=77927072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019672A BR112022019672A2 (pt) | 2020-03-30 | 2021-03-30 | Composições de vacina para o tratamento de coronavírus |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11253587B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4126038A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023519837A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230008707A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021247583A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022019672A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142132C (cg-RX-API-DMAC7.html) |
| IL (1) | IL296578A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012192A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021198769A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| US20230174591A1 (en) * | 2020-05-19 | 2023-06-08 | National Research Council Of Canada | Use of Human Resistin as a Trimerization Partner for Expression of Trimeric Proteins |
| WO2022051859A1 (en) * | 2020-09-11 | 2022-03-17 | Manuel Caruso | Pseudotyped retroviral particles for inducing immunity against coronavirus infections |
| KR102744743B1 (ko) * | 2021-10-25 | 2024-12-19 | 경희대학교 산학협력단 | SARS-CoV-2의 스파이크 단백질 전부 또는 일부를 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| WO2024243675A1 (en) * | 2023-06-02 | 2024-12-05 | Variation Biotechnologies Inc. | Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| CA2568838A1 (en) | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| AU2009316680B2 (en) | 2008-11-18 | 2016-03-24 | Takeda Vaccines, Inc. | RSV F VLPs and methods of manufacture and use thereof |
| US8920812B2 (en) | 2009-11-03 | 2014-12-30 | Takeda Vaccines, Inc. | Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS |
| WO2011115583A1 (en) * | 2010-03-19 | 2011-09-22 | National University Of Singapore | A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| WO2014128568A2 (en) * | 2013-02-25 | 2014-08-28 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of hepatitis c |
| MX2019000725A (es) * | 2016-07-18 | 2019-07-04 | Variation Biotechnologies Inc | Composiciones de vacuna para tratamiento de virus zika. |
-
2021
- 2021-03-30 JP JP2022557696A patent/JP2023519837A/ja active Pending
- 2021-03-30 AU AU2021247583A patent/AU2021247583A1/en not_active Abandoned
- 2021-03-30 MX MX2022012192A patent/MX2022012192A/es unknown
- 2021-03-30 BR BR112022019672A patent/BR112022019672A2/pt not_active IP Right Cessation
- 2021-03-30 US US17/218,148 patent/US11253587B2/en not_active Expired - Fee Related
- 2021-03-30 WO PCT/IB2021/000190 patent/WO2021198769A1/en not_active Ceased
- 2021-03-30 CA CA3142132A patent/CA3142132C/en active Active
- 2021-03-30 EP EP21782275.8A patent/EP4126038A4/en not_active Withdrawn
- 2021-03-30 IL IL296578A patent/IL296578A/en unknown
- 2021-03-30 KR KR1020227037855A patent/KR20230008707A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021198769A8 (en) | 2021-12-23 |
| WO2021198769A1 (en) | 2021-10-07 |
| US11253587B2 (en) | 2022-02-22 |
| EP4126038A4 (en) | 2024-04-17 |
| WO2021198769A9 (en) | 2022-03-03 |
| IL296578A (en) | 2022-11-01 |
| CA3142132C (en) | 2024-06-04 |
| MX2022012192A (es) | 2022-10-27 |
| AU2021247583A1 (en) | 2022-11-03 |
| CA3142132A1 (en) | 2021-10-07 |
| KR20230008707A (ko) | 2023-01-16 |
| US20210353741A1 (en) | 2021-11-18 |
| EP4126038A1 (en) | 2023-02-08 |
| JP2023519837A (ja) | 2023-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019000725A (es) | Composiciones de vacuna para tratamiento de virus zika. | |
| MX2022012192A (es) | Composiciones de vacuna para el tratamiento de coronavirus. | |
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| EA202092808A1 (ru) | Вакцины на основе наночастиц с новыми структурными компонентами | |
| JOP20210106A1 (ar) | بروتينات rsv f سابقة الاندماج مستقرة | |
| BR112016028816A2 (pt) | combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit. | |
| BR112018068748A2 (pt) | composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto | |
| CL2019003393A1 (es) | Virus oncolíticos y método. | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
| CO2021005066A2 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PH12021550441A1 (en) | Modified pedv spike protein | |
| WO2023064612A3 (en) | Pharmaceutical compositions for delivery of viral antigens and related methods | |
| BR112023016241A2 (pt) | Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos | |
| WO2021202599A3 (en) | Adeno-associated virus based compositions and related methods for inducing humoral immunity | |
| WO2014128568A3 (en) | Compositions and methods for treatment of hepatitis c | |
| CL2025001816A1 (es) | Virus oncolítico y usos del mismo. | |
| WO2020012428A8 (en) | New vaccines against avian reoviruses | |
| AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
| BR112022019334A2 (pt) | Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células | |
| PH12022550240A1 (en) | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof | |
| BR112021022270A2 (pt) | Materiais e métodos para tratar degeneração macular relacionada à idade | |
| BR112023018282A2 (pt) | Composições de vacina e métodos para tratamento de hsv |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2873 DE 27-01-2026 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |